SWK CEO sees Enteris as platform for own royalties
SWK Holdings (SWKH) is a specialized finance company with a specific focus on opportunities in the global healthcare sector. In an exclusive interview with The Fly, the company's CEO Winston Black discussed Enteris BioPharma acquisition: "Royalties are a very meaningful part of our business. And one of the challenges with royalties is actually finding them and then being able to buy them - that's not necessarily the easiest thing to do. We really like the pharmaceutical royalty market and think there's a lot of potential there. Enteris potentially gives us our own platform to generate our own royalties and not having to go find them to purchase. From the finance business perspective, it's actually exciting. I think that by bringing the formulation in manufacturing, and operations into SWK, it improves SWK's standing within the life science ecosystem. I think we'll be able to have different conversations with folks as an operating entity than just a finance business. Because of that I think we can bring different relationships and perspectives to partners since we're going to be an operator ourselves. There is a lot of synergy between the finance business and Enteris' operations. We've also had some new opportunities arise from the Enteris side of SWK house. Regarding the integration, we're fully intending for the Enteris team to continue running the business. I wouldn't say we will be totally hands off on the business, as we're certainly going to be very involved and very interested in its ultimate success. But one of the appealing things about Enteris it that there is a very deep management team with a ton of technical and operational depth and knowledge that we don't have. We're going to need them to continue to run the business and our job is to help them run it better and invest in the business to grow in ways they weren't able to grow in the past." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.